## CRM: Salesforce, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.8% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($240.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Salesforce, Inc. (CRM) Expands Partnership With USDOT**
- Source: Insider Monkey | 20251215T224700 | Bullish | Relevance: 100%
- Salesforce, Inc. (NYSE: CRM) has expanded its partnership with the U.S. Department of Transportation (USDOT) to modernize operations using its AI CRM tools, specifically deploying the Agentforce AI agent platform. This collaboration aims to automate tasks, enhance citizen support, and streamline federal grant management across various transportation networks. Despite mixed Q3 2026 results that missed revenue estimates but beat EPS forecasts, Wall Street analysts maintain a positive outlook for the company.

**2. Salesforce, Inc. (CRM) Expands Partnership With USDOT**
- Source: Insider Monkey | 20251216T040002 | Somewhat-Bullish | Relevance: 100%
- Salesforce, Inc. (NYSE: CRM) has expanded its partnership with the U.S. Department of Transportation (USDOT) to modernize operations using its AI CRM tools, including the deployment of Agentforce for automating routine tasks and boosting efficiency across various networks. This expansion builds on previous collaborations focused on real-time data sharing and federal grant management. Despite missing revenue estimates for Q3 2026, Salesforce reported strong EPS and raised its full-year guidance, with Wall Street maintaining a positive outlook.

**3. Salesforce (CRM) Stock After Hours Today (Dec. 15, 2025): Why Shares Fell, What’s Moving the AI Thesis, and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251215T230820 | Neutral | Relevance: 99%
- Salesforce (CRM) shares fell on Monday, December 15, 2025, influenced by a broader market shift away from AI and mega-cap tech stocks, along with macro data risks. Despite the decline, analysts remain largely bullish on Salesforce's long-term AI monetization potential through its Agentforce platform. Investors are keenly watching the upcoming U.S. Jobs Report and Salesforce's Agentforce World Tour Chicago event for any catalysts that could impact the stock.

**4. Salesforce Stock (CRM) Slides on Dec. 15, 2025 as Wall Street Keeps Bullish Forecasts on Agentforce AI**
- Source: ts2.tech | 20251215T174759 | Neutral | Relevance: 97%
- Salesforce (CRM) shares fell over 3% on December 15, 2025, to around $254, despite positive analyst commentary and new customer adoption for its Agentforce AI. Analysts largely maintain bullish forecasts, with an average price target around $326-$330, reflecting confidence in Salesforce's AI monetization potential. However, the market remains concerned about whether enterprises will pay significantly for AI features in CRM, influencing investor sentiment.

**5. After Earnings, Is Salesforce Stock a Buy, a Sell, or Fairly Valued?**
- Source: Morningstar | 20251216T111107 | Somewhat-Bullish | Relevance: 96%
- Morningstar maintains its fair value estimate of $325 per share for Salesforce (CRM) after its fiscal third-quarter earnings report, seeing the stock as attractive despite increased scrutiny on its seat-based model. The company's revenue grew 8% in constant currency, with strong momentum in artificial intelligence through Agentforce and Data 360 annual recurring revenue. Salesforce is expected to accelerate revenue within 12-18 months and is assigned a wide economic moat rating due to switching costs and network effects.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Morgan Stanley | $398 | $405 | -2% |
| 2025-12-08 | Citigroup | $257 | $253 | +2% |
| 2025-12-05 | DA Davidson | $235 | $225 | +4% |
| 2025-12-04 | Truist Securiti | $380 | $400 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Morgan Stanley | main | Overweight |
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-05 | DA Davidson | main | Neutral |
| 2025-12-04 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 6 ($26.11M) |
| Sells | 51 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.8%)
- Blackrock Inc.: 8.7% (-0.5%)
- State Street Corpora: 5.3% (+0.3%)
- JPMORGAN CHASE & CO: 2.8% (+46.5%)
- Geode Capital Manage: 2.2% (+0.6%)

### Key Risks

1. Heavy insider selling: $13M sold (51 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Quality metrics strong (margin 18%). Balance sheet: $2.2B free cash flow. Analyst sentiment negative (10 target cuts vs 6 raises). Insider buying signal ($26.1M), management confidence. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $242.4B |
| Beta | 1.25 |
| 52W Range | $221.96 - $367.09 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 19.5 |
| Current P/E | 21.6 |
| YoY Growth | 11.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 6.7% to 1.8% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.2pp (needs >3.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (2.73), confirming momentum. RSI neutral at 57. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.75% (CS: 45) | Neutral |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | 2.73 | Bullish |
| vs SMA20 | 1.050x | Above |
| vs SMA50 | 1.035x | Above |
| vs SMA200 | 0.986x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $254.58
- **Stop Loss:** $240.20 (5.6% risk)
- **Target:** $268.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $17,566.02
- **Portfolio %:** 17.57%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $3.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.86 | $3.25 | +13.6% |
| 2025Q3 | $2.78 | $2.91 | +4.7% |
| 2025Q2 | $2.55 | $2.58 | +1.3% |
| 2025Q1 | $2.61 | $2.78 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*